MedPath

Effect of Topiramate in treatment of chronic schizophrenia

Not Applicable
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT138904014236N1
Lead Sponsor
Mashad university of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Inclusion criteria
1. All the patients who meet the full criteria of chronic and treatment resistant schizophrenia disorder, based on DSMIV-TR
2. Ages of subjects were between 25 to 65 years
3. All patients were hospitalized for at least 6 month before the study
4. All patients were being treated with Clozapin

Exclusion criteria
1. Chronic diseases including diabetes, hypertension, history of kidney stone, epilepsy and substance abuse
2. An ongoing medical treatment
3. Elevated PANSS score up to 30%
4. Adverse effects associated with therapy including dizziness, agitation, hypertension, allergy to medications
5. Medical problems need to be treated such as diarrhea, urinary infection, cardiovascular disease, and trauma.
6. Temporary or permanent discharge from hospital while in study
7. Developing new psychiatric symptoms such as manic or hypomanic episode, panic attack

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath